Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (Text with EEA relevance)

	CHAPTER I
	SCOPE AND DEFINITIONS
Article 1 Article 2 Article 3	Purpose and subject matter Scope Definitions
	CHAPTER II
	APPROVAL OF ACTIVE SUBSTANCES
Article 4 Article 5 Article 6 Article 7 Article 8 Article 9 Article 10 Article 11	Conditions for approval Exclusion criteria Data requirements for an application Submission and validation of applications Evaluation of applications Approval of an active substance Active substances which are candidates for substitution Technical guidance notes
	CHAPTER III
RENEWA	L AND REVIEW OF APPROVAL OF AN ACTIVE SUBSTANCE
Article 12 Article 13 Article 14 Article 15 Article 16	Conditions for renewal Submission and acceptance of applications Evaluation of applications for renewal Review of approval of an active substance Implementing measures
	CHAPTER IV
	GENERAL PRINCIPLES CONCERNING THE AUTHORISATION OF BIOCIDAL PRODUCTS
Article 17 Article 18 Article 19 Article 20 Article 21 Article 22	Making available on the market and use of biocidal products Measures geared to the sustainable use of biocidal products Conditions for granting an authorisation Requirements for applications for authorisation Waiving of data requirements Content of authorisation

Comparative assessment of biocidal products

Technical guidance notes

Article 23

Article 24

CHAPTER V

	SIMPLIFIED AUTHORISATION PROCEDURE
Article 26 A	ligibility for the simplified authorisation procedure applicable procedure
	Making available on the market of biocidal products authorised in coordance with the simplified authorisation procedure
	amendment of Annex I
	CHAPTER VI
NATI	ONAL AUTHORISATIONS OF BIOCIDAL PRODUCTS
	ubmission and validation of applications
Article 30 E	valuation of applications
Article 31 R	enewal of a national authorisation
	CHAPTER VII
	MUTUAL RECOGNITION PROCEDURES
	authorisation through mutual recognition
	Iutual recognition in sequence
	Iutual recognition in parallel
	eferral of objections to the coordination group
	eferral of unresolved objections to the Commission
Article 37 D	Derogations from mutual recognition
	Opinion of the Agency
	application for mutual recognition by official or scientific bodies upplementary rules and technical guidance notes
	CHAPTER VIII
UN	IION AUTHORISATIONS OF BIOCIDAL PRODUCTS
	SECTION 1
	Granting of Union authorisations
Article 42 B Article 43 Si	Union authorisation biocidal products for which Union authorisation may be granted ubmission and validation of applications valuation of applications
	SECTION 2

Renewal of Union authorisations

Article 45	Submission and acceptance of applications
Article 46	Evaluation of applications for renewal

CHAPTER IX

CANCELLATION, REVIEW AND AMENDMENT OF AUTHORISATIONS

Article 47 Article 48 Article 49	Obligation for notification of unexpected or adverse effects Cancellation or amendment of an authorisation Cancellation of an authorisation at the request of the authorisation holder
Article 50	Amendment of an authorisation at the request of the authorisation holder
Article 51 Article 52	Detailed rules Period of grace
	CHAPTER X
	PARALLEL TRADE
Article 53	Parallel trade
	CHAPTER XI
	TECHNICAL EQUIVALENCE
Article 54	Assessment of technical equivalence
	CHAPTER XII
	DEROGATIONS
Article 55 Article 56 Article 57	Derogation from the requirements Research and development Exemption from registration under Regulation (EC) No 1907/2006
	CHAPTER XIII
	TREATED ARTICLES
Article 58	Placing on the market of treated articles
	CHAPTER XIV
	DATA PROTECTION AND DATA-SHARING
Article 59 Article 60 Article 61 Article 62 Article 63	Protection of data held by competent authorities or the Agency Data protection periods Letter of access Data sharing Compensation for data sharing
Article 64	Use of data for subsequent applications

CHAPTER XV

INFORMATION AND COMMUNICATION

SECTION 1

Monitoring and reporting

Article 65 Article 66 Article 67 Article 68	Compliance with requirements Confidentiality Electronic public access Record-keeping and reporting
	SECTION 2
	Information about biocidal products
Article 69 Article 70 Article 71 Article 72 Article 73	Classification, packaging and labelling of biocidal products Safety data sheets Register for Biocidal Products Advertising Poison control
	CHAPTER XVI
	THE AGENCY
Article 74 Article 75 Article 76 Article 77 Article 78 Article 79	Role of the Agency Biocidal Products Committee Secretariat of the Agency Appeal The budget of the Agency Formats and software for submission of information to the Agency
	CHAPTER XVII
	FINAL PROVISIONS
Article 80 Article 81 Article 82 Article 83 Article 84 Article 85 Article 86 Article 87 Article 88 Article 88	Fees and charges Competent authorities Committee procedure Exercise of the delegation Urgency procedure Adaptation to scientific and technical progress Active substances included in Annex I to Directive 98/8/EC Penalties Safeguard clause Transitional measures

Transitional measures concerning active substances evaluated

Transitional measures concerning applications for biocidal product authorisations submitted under Directive 98/8/EC

under Directive 98/8/EC

Article 90

Article 91

Status: This is the original version (as it was originally adopted).

Article 92	Transitional measures concerning biocidal products authorised/
Article 93	registered under Directive 98/8/EC Transitional measures concerning biocidal products not covered by the scope of Directive 98/8/EC
Article 94	Transitional measures concerning treated articles
Article 95	Transitional measures concerning access to the active substance
	dossier
Article 96	Repeal
Article 97	Entry into force
	Signature

ANNEX I

ANNEX II

INFORMATION REQUIREMENTS FOR ACTIVE SUBSTANCES

- 1. This Annex sets out the information requirements for the preparation...
- 2. The data elements set down in this Annex comprise a...
- 3. A detailed and full description of the studies conducted or...
- 4. The formats made available by the Agency must be used...
- 5. Tests submitted for the purpose of the approval of an...
- 6. Tests performed should comply with the relevant requirements of protection...
- 7. Where testing is done, a detailed description (specification) of the...
- 8. Where test data exist that have been generated before 1...
- 9. New tests involving vertebrates shall be conducted as the last...

TITLE 1

CHEMICAL SUBSTANCES

Core data set and additional data set for active substances...

TITLE 2

MICRO-ORGANISMS

Core data set and additional data set for active substances...

ANNEX III

INFORMATION REQUIREMENTS FOR BIOCIDAL PRODUCTS

- 1. This Annex sets out the information requirements that shall be...
- 2. The data elements set down in this Annex comprise a...
- 3. A detailed and full description of studies conducted and of...
- 4. The formats made available by the Agency shall be used...
- 5. Tests submitted for the purpose of authorisation shall be conducted...
- 6. Tests performed should comply with the relevant requirements of protection...
- 7. Where testing is done, a detailed quantitative and qualitative description...
- 8. Where test data exist that have been generated before 17...
- 9. New tests involving vertebrates shall be conducted as the last...

TITLE 1

CHEMICAL PRODUCTS

Core data set and additional data set for chemical products...

TITLE 2

MICRO-ORGANISMS

Core data set and additional data set

ANNEX IV

GENERAL RULES FOR THE ADAPTATION OF THE DATA REQUIREMENTS

This Annex sets out rules to be followed when the...

The reasons for such adaptations to the data requirements must...

- 1. TESTING DOES NOT APPEAR SCIENTIFICALLY NECESSARY
 - 1.1. Use of existing data
 - 1.1.1. Data on physical-chemical properties from experiments not carried out according...
 - 1.1.2. Data on human health and environmental properties from experiments not...
 - 1.1.3. Historical human data
 - 1.2. Weight of evidence
 - 1.3. Qualitative or Quantitative structure-activity relationship ((Q)SAR)
 - 1.4. In vitro methods
 - 1.5. Grouping of substances and read-across approach
- 2. TESTING IS TECHNICALLY NOT POSSIBLE

3. PRODUCT-TAILORED EXPOSURE-DRIVEN TESTING

- 3.1. Testing in accordance with some endpoints in Sections 8 and...
- 3.2. In all cases, adequate justification and documentation shall be provided....

ANNEX V

BIOCIDAL PRODUCT-TYPES AND THEIR DESCRIPTIONS AS REFERRED TO IN ARTICLE 2(1)

MAIN CONCOMPEdants

Product-Hypealn hygiene

Product-Dipinfectants and algaecides not intended for direct application to humans...

Product-Wepter inary hygiene Product-Troppel 4 and feed area

Product-Dypeking water

MAIN CPRESETPATIVES

Product-Pyece6vatives for products during storage

Product-Fylpre preservatives

Product-Wped8preservatives

Product-Fylpæ9leather, rubber and polymerised materials preservatives

Product-Coppestruction material preservatives

Product-Pypeet Vatives for liquid-cooling and processing systems

Product-Stymeic 2des

Product-Working or cutting fluid preservatives

MAIN CPRESIDE OP 18 rol

Product-Rypotentacides

Product-Ameid6s

Product MpHuscicides, vermicides and products to control other invertebrates

Product-Prisociclides

Product-Invsectionides, acaricides and products to control other arthropods

Product-RepellOnts and attractants

Product-Copetr20: of other vertebrates

MAIN CORDED Biocidal products

Product-Ampter duling products

Product-Expbalaning and taxidermist fluids

ANNEX VI

COMMON PRINCIPLES FOR THE EVALUATION OF DOSSIERS FOR BIOCIDAL PRODUCTS

TERMS AND DEFINITIONS

Technical definitions

- (a) Hazard identification
- (b) Dose (concentration) response (effect) assessment
- (c) Exposure assessment
- (d) Risk characterisation
- (e) Environment

INTRODUCTION

- 1. This Annex sets out the common principles for the evaluation...
- 2. The principles set out in this Annex can be applied...
- 3. In order to ensure a high and harmonised level of...
- 4. A risk assessment on the active substance(s) present in the...
- 5. Additional risk assessments shall be carried out, in the same...
- 6. In order to carry out a risk assessment, data are...
- 7. The results of the risk assessments carried out on the...
- 8. When making evaluations of a biocidal product the evaluating body...
- 9. The application of these common principles shall, when taken together...
- 10. In the case of biocidal products containing active substances covered...
- 11. During the process of evaluation, applicants and the evaluating bodies...
- 12. The judgments made by the evaluating body during the evaluation...

ASSESSMENT

General principles

- 13. The data submitted in support of an application for authorisation...
- 14. A risk assessment on the active substance present in the...
- 15. In carrying out the assessment, the possibility of cumulative or...
- 16. For each active substance and each substance of concern present...
- 17. The results arrived at from a comparison of the exposure...
- 18. The risk assessment shall determine:
- 19. In certain cases it may be concluded that further data...
- 20. The information provided on the biocidal product family shall permit...
- 21. Where relevant the technical equivalence for every active substance contained...

Effects on human and animal health

Effects on human health

- 22. The risk assessment shall take account of the following potential...
- 23. The effects previously mentioned result from the properties of the...
- 24. The populations previously mentioned are:
- 25. The hazard identification shall address the properties and potential adverse...
- 26. The evaluating body shall apply points 27 to 30 when...
- 27. For repeated dose toxicity and reproductive toxicity the dose-response relationship...
- 28. For acute toxicity, corrosivity and irritation, it is not usually...
- 29. For mutagenicity and carcinogenicity, a non-threshold assessment should be carried...
- 30. With respect to skin sensitisation and respiratory sensitisation, in so...
- 31. When carrying out the risk assessment special consideration shall be...
- 32. An exposure assessment shall be carried out for each of...
- 33. The exposure assessment shall be based on the information in...
- 34. When conducting the exposure assessment, special consideration shall be given...
- 35. Where, for any of the effects set out in point...

Effects on animal health

36. Using the same relevant principles as described in the section...

Effects on the environment

- 37. The risk assessment shall take account of any adverse effects...
- 38. The hazard identification shall address the properties and potential adverse...
- 39. A dose (concentration) response (effect) assessment shall be carried...
- 40. The PNEC shall be determined from the data on effects...
- 41. An assessment factor is an expression of the degree of...
- 42. For each environmental compartment, an exposure assessment shall be carried...
- 43. A PEC, or where necessary a qualitative estimate of exposure,...
- 44. The PEC, or the qualitative estimation of exposure, shall be...
- 45. When conducting the exposure assessment, special consideration shall be given...
- 46. For any given environmental compartment, the risk characterisation shall, as...
- 47. If it has not been possible to derive a PEC/PNEC...
- 48. The evaluating body shall conclude that the biocidal product does...

Effects on target organisms

- 49. An assessment shall be made to demonstrate that the biocidal...
- 50. The evaluating body shall, where relevant, evaluate the possibility of... Efficacy
- 51. Data submitted by the applicant shall be sufficient to substantiate...
- 52. Testing should be carried out according to Union guidelines where... Summary
- 53. In each of the areas where risk assessments have been...
- 54. For biocidal product containing more than one active substance, any...

CONCLUSIONS

General principles

- 55. The purpose of the evaluation is to establish whether or...
- 56. In establishing compliance with the criteria set out in point...
- 57. The evaluating body shall, when seeking to establish whether a...
- 58. If the conclusion arrived at by the evaluating body is...

Effects on human and animal health

Effects on human health

- 59. The evaluating body shall consider possible effects on all human...
- 60. The evaluating body shall examine the relationship between exposure and...
- 61. Typically, the margin of exposure (MOEref) the ratio between...
- 62. The evaluating body shall, where appropriate, conclude that criterion (iii)...
- 63. If, for non-professional users, the wearing of personal protective equipment...

Effects on animal health

64. Using the same relevant criteria as described in the section...

Effects on the environment

- 65. The basic tool used in the decision-making is the PEC/PNEC...
- 66. For any given environmental compartment, if the PEC/PNEC ratio is... Water

- 67. The evaluating body shall conclude that the biocidal product does...
- 68. The evaluating body shall conclude that the biocidal product does...
- 69. The evaluating body shall conclude that the biocidal product does...
- 70. The proposed instructions for use of the biocidal product, including...

Soil

71. The evaluating body shall conclude that the biocidal product does...

Air

72. The evaluating body shall conclude that the biocidal product does...

Non-target organisms

- 73. The evaluating body shall conclude that the biocidal product does
- 74. The evaluating body shall conclude that the biocidal product does...

Effects on target organisms

- 75. Where the development of resistance or cross-resistance to the active...
- 76. A biocidal product intended to control vertebrates shall not normally... Efficacy
- 77. The level, consistency and duration of protection, control or other... Summary
- 78. In relation to the criteria set out in points (iii)...

OVERALL INTEGRATION OF CONCLUSIONS

ANNEX VII

Status: This is the original version (as it was originally adopted).

- (1) OJ C 347, 18.12.2010, p. 62.
- (2) Position of the European Parliament of 22 September 2010 (OJ C 50 E, 21.2.2012, p. 73) and position of the Council at first reading of 21 June 2011 (OJ C 320 E, 1.11.2011, p. 1). Position of the European Parliament of 19 January 2012 (not yet published in the Official Journal) and decision of the Council of 10 May 2012.
- (**3**) OJ L 123, 24.4.1998, p. 1.
- (4) OJ L 396, 30.12.2006, p. 1.
- (5) OJ L 189, 20.7.1990, p. 17.
- **(6)** OJ L 169, 12.7.1993, p. 1.
- (7) OJ L 331, 7.12.1998, p. 1.
- (8) OJ L 342, 22.12.2009, p. 59.
- **(9)** OJ L 31, 1.2.2002, p. 1.
- (10) OJ L 268, 18.10.2003, p. 29.
- (11) OJ L 354, 31.12.2008, p. 16.
- (12) OJ L 312, 22.11.2008, p. 3.
- (13) OJ L 55, 28.2.2011, p. 13.